Inovio Pharmaceuticals Stock Price To Book
| INO Stock | USD 4.19 0.18 4.49% |
Inovio Pharmaceuticals fundamentals help investors to digest information that contributes to Inovio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Inovio Stock. The fundamental analysis module provides a way to measure Inovio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inovio Pharmaceuticals stock.
As of the 27th of November 2024, Price To Book Ratio is likely to drop to 1.10. Inovio | Price To Book |
Inovio Pharmaceuticals Company Price To Book Analysis
Inovio Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Inovio Pharmaceuticals Price To Book | 1.47 X |
Most of Inovio Pharmaceuticals' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inovio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inovio Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Inovio Pharmaceuticals is extremely important. It helps to project a fair market value of Inovio Stock properly, considering its historical fundamentals such as Price To Book. Since Inovio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inovio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inovio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Inovio Price To Book Historical Pattern
Today, most investors in Inovio Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inovio Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to book growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Inovio Pharmaceuticals price to book as a starting point in their analysis.
Inovio Pharmaceuticals Price To Book |
| Timeline |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Inovio Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Inovio Pharmaceuticals has a Price To Book of 1.4658 times. This is 94.29% lower than that of the Biotechnology sector and 75.73% lower than that of the Health Care industry. The price to book for all United States stocks is 84.59% higher than that of the company.
Inovio Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Inovio Pharmaceuticals by comparing valuation metrics of similar companies.Inovio Pharmaceuticals is currently under evaluation in price to book category among its peers.
Inovio Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inovio Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inovio Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Inovio Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (329.46) % | ||||
| Current Valuation | 35.43 M | ||||
| Shares Outstanding | 26.1 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 33.51 % | ||||
| Number Of Shares Shorted | 3.5 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.47 X | ||||
| Price To Sales | 176.83 X | ||||
| Revenue | 832.01 K | ||||
| Gross Profit | (177.39 M) | ||||
| EBITDA | (130.39 M) | ||||
| Net Income | (135.12 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 30.21 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 5.15 X | ||||
| Cash Flow From Operations | (124.37 M) | ||||
| Short Ratio | 11.22 X | ||||
| Earnings Per Share | (4.43) X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 127 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 104.66 M | ||||
| Total Asset | 172.94 M | ||||
| Retained Earnings | (1.62 B) | ||||
| Working Capital | 110.54 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
| Net Asset | 172.94 M |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock: Check out Inovio Pharmaceuticals Piotroski F Score and Inovio Pharmaceuticals Altman Z Score analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.